ArticleDiscover oncology2025
Clinical value of the novel inflammatory-nutritional marker PALR in predicting early postoperative recurrence of colorectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study.Breast (Edinburgh, Scotland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe purpose of this study is to evaluate the clinical application value of (platelet × albumin)/lymphocyte ratio (PALR) as a novel prognostic indicator in predicting early postoperative recurrence in colorectal cancer (CRC) patients who have undergone radical surgery. By investigating the association between this inflammatory marker and disease progression, it aims to provide a theoretical basis for early clinical intervention.
methodsClinical data of 739 patients diagnosed with primary colorectal cancer (CRC) in our hospital between February 2022 and May 2023 were retrospectively included. The non-linear association between PALR and the risk of early postoperative recurrence was explored using restricted cubic spline (RCS) analysis, and a receiver operating characteristic (ROC) curve was constructed to evaluate the predictive efficacy of PALR. Patients were stratified into high- and low-PALR groups based on the optimal cutoff value derived from Youden’s index. Univariate and multivariate logistic regression models were used to identify independent predictors of early postoperative recurrence, and sensitivity analysis with PALR quartiles was performed to validate the stability of primary findings.
resultsA total of 340 eligible primary colorectal cancer (CRC) patients were retrospectively enrolled in this study. The area under the receiver operating characteristic (ROC) curve of PALR for predicting early postoperative recurrence or metastasis in CRC patients was 0.659. Restricted cubic spline (RCS) analysis revealed a linear ascending trend between PALR and early postoperative recurrence risk (P value for non-linearity = 0.276). Multivariate logistic regression identified PALR as an independent predictor of early postoperative recurrence (odds ratio [OR] = 2.65, 95% confidence interval [CI]: 1.12–6.39, P = 0.026). A nomogram model incorporating PALR and other independent predictors was constructed, with an internally validated concordance index (C-index) of 0.835. Calibration plots and decision curve analysis (DCA) supported the favorable predictive performance and clinical utility of the model, while sensitivity analysis further confirmed the robustness of our findings.
conclusionThe PALR serves as an independent predictor for early postoperative recurrence in colorectal cancer (CRC) patients, demonstrating substantial clinical utility in risk assessment and guiding personalized intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.